The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Previous studies investigating the outcome of allogeneic hematopoietic cell transplantation (allo-HCT) in relapsed patients with acute myeloid leukemia (AML), have established that certain factors such as duration of first complete remission (CR1) or age at relapse, could predict the likelihood of CR2. Achieving CR2 has been shown to provide a benefit for subsequent allo-HCT.1
However, so far there are no available data from large series, which assess the impact of conditioning regimen intensity on the outcomes of HCT in patients with AML in CR2.
Maria H Gilleece, Leeds Teaching Hospitals Trust, Leeds, UK, and colleagues, conducted a study2 on behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Bone Marrow Transplantation (EBMT) to evaluate the difference between reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) in patients with AML who were in CR2, including by age (<50 versus ≥50 years).
Two-year survival outcomes are shown in Table 1 (whole cohort) and Table 2 (by conditioning regimen).
Table 1. Two-year outcomes post-allo-HCT in the cohort
Percentage (%)
95% CI
LFS
52
49.4-54.5
OS
58.7
56.2-61.2
RI
28.9
26.7-31.2
NRM
19
17.2-21
GFRS
38.7
36.2-41.1
cGvHD
37.2
34.7-39.7
Extensive cGvHD
15.9
14.1-17.8
Table 2. Two-year outcomes of allo-HCT in CR2 by conditioning regimen and age
LFS (%)
OS (%)
NRM (%)
GRFS (%)
Patients <50 years old
MAC
54
61
18
38
RIC
54
62
15
42
p value
0.61
0.7
Not reported (NR)
NR
Patients ≥50 years old
MAC
52
58
27
42.4
RIC
49
55
19
36
p value
0.7
0.3
NR
NR
In order to assess the impact of conditioning regimens and other parameters on transplant outcomes, multivariate analysis was conducted (Table 3).
Factor
Outcome
Effect
Hazard ratio (HR) and confidence interval
p values
Conditioning regimen, RIC
NRM
Favored RIC
0.65 (0.5–0.84)
0.001
Conditioning regimen RIC, and age ≥50 years
NRM
Favored RIC
0.54 (0.38–0.76)
<0.001
Conditioning regimen RIC, and age ≥50 years
cGVHD
Increased
1.38 (1.03–1.85)
0.03
Age <50 years
GRFS
Adverse
1.13 (1.01–1.26)
0.03
Age <50 years
NRM
Increased
1.25 (1.01–1.53)
0.034
Age ≥50 years
NRM
Increased
1.6 (1.21–2.03)
0.001
Karnofsky performance scores (KPS) >80% and age <50 years
NRM
Lowered
0.447 (0.219–0.914)
0.03
KPS >80% and age ≥50 years
NRM
Lowered
0.265 (0.162–0.435)
<10-5
KPS >80% and age ≥50 years
aGvHD grade II-IV
aGvHD grade III-IV
Lowered
0.562 (0.322–0.982)
0.338 (0.152–0.748)
0.043
0.007
KPS >80% and age ≥50 years
OS
LFS
GRFS
Improved
0.437 (0.297–0.645)
0.486 (0.331–0.715)
0.363 (0.254–0.518)
<10-4
<10-3
0.000
Longer interval from diagnosis to allo-HCT and age <50 years
RI
LFS
OS
GRFS
Improved
0.96 (0.948–0.975)
0.982 (0.974–0.99)
0.982 (0.974–0.991)
0.991 (0.985–0.997)
<10-5
10-5
<10-4
0.003
Longer interval from diagnosis to allo-HCT and age ≥50 years
RI
LFS
OS
GRFS
Improved
0.974 (0.963–0.986)
0.987 (0.98–0.995)
0.988 (0.98–0.996)
0.993 (0.986–1)
10-5
0.001
0.002
0.037
Donor selection: MMVUD or Haplo-ID or donors and age <50 years
NRM
Increased
MMVUD: 1.986 (1.168–3.377)
Haplo-ID: 2.096 (1.097–4.002)
0.01
0.02
Donor selection: MMVUD or Haplo-ID or donors and age ≥50 years
NRM
Increased
MMVUD: 2.241 (1.419–3.539)
Haplo-ID: 1.948 (1.069–3.552)
0.001
0.029
Donor selection: MMVUD or Haplo-ID donors and age ≥50 years
aGvHD grade II–IV
Increased
MMVUD: 2.685 (1.692–4.26)
Haplo-ID: 2.434 (1.341–4.417)
<10-4
0.003
Donor selection: MMVUD donors and age <50 years
aGvHD grade II–IV
Increased
2.679 (1.721–4.17)
<10-4
Donor selection: female donors and age <50 years
Extensive cGvHD
Increased
1.515 (1.047–2.194)
0.028
Donor source: PBSC and age <50 years
cGvHD
Increased
1.784 (1.253–2.539)
0.001
Donor source: PBSC and age ≥50 years
cGvHD
Increased
1.683 (1.08–2.624)
0.021
Advantages
Limitations
Wide range of regimens included
Retrospective
Long follow-up
Only addresses patients in CR2 rather than relapse after CR1
Large sample size
Unknown reasons that allo-HCT was used in CR2
The high relapse rates in patients with AML in CR2 indicate an unmet need for more active therapies.
References